Dr. George Demetri on the Mutagenic Properties and Future Potentials of DacarbazineDecember 5th 2015
George Demetri, MD, professor of medicine, Harvard Medical School, director of the Sarcoma Center, Dana Farber Brigham Women's Cancer Center, on the mutagenic properties of dacarbazine.
Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue SarcomaDecember 4th 2015
Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma.
Addition of Olaratumab to Doxorubicin Extends Survival by Nearly One Year in Soft Tissue SarcomaNovember 7th 2015
The addition of olaratumab to doxorubicin improved overall survival (OS) by nearly 1 year in patients with advanced soft tissue sarcoma, according to final results of a phase Ib/II study.
Immunotherapy and Chemotherapy Trial Arm for Sarcoma CommencesSeptember 24th 2015
A sarcoma study arm of the phase II portion of the multiarm PembroPlus clinical trial that combines immunotherapy with chemotherapy has commenced at Cancer Treatment Centers of America (CTCA), Western Regional Medical Center, Goodyear, Arizona
Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPCJuly 7th 2015
Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).
Study Shows First-Time Survival Benefit for Soft Tissue SarcomaJune 2nd 2015
Marking the first time a phase III study has shown a survival advantage for patients with soft tissue sarcoma, treatment with eribulin (Halaven) demonstrated improved overall survival (OS) by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
Building a Better Molecular Mouse Trap: Circulating Tumor DNA Detects Resistance Mutations in Lung CancerApril 17th 2015
The availability of mutation-specific treatments and an increasing understanding of potential resistance mechanisms have provided immense opportunities for research and development of new therapies in lung cancer.
Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.
Developing Next-Generation Anti-Androgen Therapies for CRPCMarch 21st 2014
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer
AR Findings Highlight Detailed Tumor-Profiling StudyMarch 7th 2014
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.